Gluscan (Fludeoxyglucose (18f))

Gluscan is a radiopharmaceutical product containing the active ingredient fludeoxyglucose (18F) supplied as a sterile solution for injection. It is marketed in the European Union and is available only by prescription. The compound is a fluorine‑18 labeled glucose analog used in positron emission tomography (PET) imaging to assess metabolic activity in various tissues. Gluscan is administered intravenously under controlled conditions and interpreted by qualified physicians.

Gluscan is indicated for diagnostic PET imaging in several clinical specialties.

- Oncologic PET imaging for tumor detection, staging, and treatment monitoring - Cardiac PET imaging to assess myocardial viability and perfusion - Neurologic PET imaging for brain metabolism, epilepsy evaluation, and dementia assessment - Pediatric oncology imaging when appropriate and dose‑adjusted - Research applications such as pharmacokinetic and drug‑development studies

Adverse reactions to Gluscan are generally mild, but rare serious events have been reported.

Common: - Nausea or mild gastrointestinal discomfort - Transient flushing or warmth at the injection site - Injection site pain or bruising - Mild headache or dizziness

Serious: - Allergic reactions including anaphylaxis - Severe hypoglycemia, especially in diabetic patients - Radiation‑related skin erythema or ulceration - Acute renal impairment in susceptible individuals

Use of Gluscan requires careful consideration of patient‑specific factors and procedural safeguards.

- Verify pregnancy status and defer use unless benefits outweigh risks - Ensure adequate patient hydration before and after injection - Check fasting blood glucose levels; correct significant hyper‑ or hypoglycemia - Apply standard radiation protection measures for staff and family members - Avoid use in patients with known severe allergy to radiopharmaceuticals - Adjust dosing for pediatric patients according to weight or surface area - Review recent exposure to other radiopharmaceuticals or high‑dose imaging studies

Gluscan may interact with other agents that affect glucose metabolism or radiation exposure.

Avoid: - Concurrent administration of high‑dose iodinated contrast agents within 24 hours - Use of another PET radiotracer within 24 hours of Gluscan injection

Use with caution: - Antidiabetic medications (insulin, sulfonylureas, metformin) that may alter glucose levels - Drugs that modify myocardial perfusion (e.g., vasodilators, beta‑blockers) - Recent chemotherapy or radiotherapy that could affect tissue uptake - Agents that increase serum calcium or phosphate levels - Substances influencing renal clearance such as diuretics or nephrotoxic drugs